Trial Profile
A retrospective, observational study comparing clinical outcomes of adults with T2D switching from Insulin Glargine 100 U/mL (Gla-100) or Insulin Detemir (IDet) to Insulin Glargine 300 U/mL (Gla-300) or Insulin Degludec (IDeg)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 21 Feb 2019
Price :
$35
*
At a glance
- Drugs Insulin degludec (Primary) ; Insulin glargine (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms DELIVER D+
- 20 Jul 2018 New trial record
- 26 Jun 2018 Results from subgroups of this trial presented at the 78th Annual Scientific Sessions of the American Diabetes Association
- 26 Jun 2018 Results presented at the 78th Annual Scientific Sessions of the American Diabetes Association